Panicogens in patients with post-traumatic stress disorder (PTSD)

Current Pharmaceutical Design

Volumn 18, Issue 35, 2012, Pages 5608-5618

  Muhtz, Christoph ^a   Wiedemann, Klaus ^a   Kellner, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CCK 4; CO2; Flashback; Flumazenil; Lactate; m CPP; Panic; Panicogen; PTSD; Yohimbine

Indexed keywords

CARBON DIOXIDE; FENFLURAMINE; FLUMAZENIL; ISOPRENALINE; LACTATE SODIUM; PLACEBO; YOHIMBINE;

ANXIETY DISORDER; CLINICAL TRIAL; DSM-IV; HUMAN; NEUROBIOLOGY; PANIC; PANICOGEN; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; MENTAL RECALL; NEUROBIOLOGY; RESEARCH DESIGN; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84870176695     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803530817     Document Type: Review

References (123)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
2. Kessler DC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995; 52(12): 1048-60.
3. Alonso J, Angermeyer MC, Bernert S, et al. 12-month comorbidity patterns and associated factors in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 109: 28-37.
4. Kolassa IT, Ertl V, Eckart C, et al. Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: Evidence from survivors of the Rwandan genocide. J Clin Psychiatry 2010; 71(5): 543-47.
5. Qureshi SU, Pyne JM, Magruder KM, Schulz PE, Kunik ME. The link between post-traumatic stress disorder and physical comorbidities: A systematic review. Psychiatr Q 2009; 80(2): 87-97.
6. Muhtz C, Godemann K, von Alm C, et al. Effects of chronic posttraumatic stress disorder on metabolic risk, quality of life, and stress hormones in aging former refugee children. J Nerv Ment Dis 2011; 199(9): 646-52.
7. Perkonigg A, Pfister H, Stein MB, et al. Longitudinal course of posttraumatic stress disorder and posttraumatic stress disorder symptoms in a community sample of adolescents and young adults. Am J Psych 2005; 162(7): 1320-7.
8. Nemeroff CB, Bremner JD, Foa EB, Mayberg HS, North CS, Stein MB. Posttraumatic stress disorder: A state-of-the-science review. J Psychiatr Res 2006; 40(1): 1-21.
9. de Kloet CS, Vermetten E, Geuze E, Kavelaars A, Heijnen CJ, Westenberg HG. Assessment of HPA-axis function in posttraumatic stress disorder: Pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res 2006; 40(6): 550-67.
10. Muhtz C, Wester M, Yassouridis A, Wiedemann K, Kellner M. A combined dexamethasone/corticotropin-releasing hormone test in patients with chronic PTSD--first preliminary results. J Psychiatr Res 2008; 42(8): 689-93.
11. Burnstein A. Posttraumatic flashbacks, dream disturbances and mental imagery. J Clin Psychiatry 1985; 46: 374-8.
12. Brewin CR: Intrusive autobiographical memories in depression and posttraumatic stress disorder. Appl Cogn Psychology 1998; 12: 359-70.
13. Frankel FH. The concept of flashbacks in historical perspective. Int J Clin Exp Hypnosis 1994; 42: 321-336.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). 1987 Washington, DC: APA.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). 1994 Washington, DC: APA.
16. Bryant RA, O'Donnell ML, Creamer M, McFarlane AC, Silove D. Posttraumatic intrusive symptoms across psychiatric disorders. J Psychiatr Res 2011; 45(6): 842-7.
17. O'Donnell ML, Elltiot P, Lau W, Creamer M. PTSD symptom trajectories: From early to chronic response. Beh Res Ther 2007; 45(3): 601-6.
18. Resick PA, Miller MW. Posttraumatic stress disorder: anxiety or traumatic stress disorder? J Trauma Stress 2009; 22(5): 384-90.
19. Stein DJ, Craske MG, Friedman MJ, Phillips KA. Meta-structure issues for the DSM-5: how do anxiety disorders, obsessivecompulsive and related disorders, post-traumatic disorders, and dissociative disorders fit together? Curr Psychiatry Rep 2011; 13(4): 248-50.
20. Brown TA, McNiff J. Specificity of autonomic arousal to DSM-IV panic disorder and posttraumatic stress disorder. Beh Res Ther 2009; 47(6): 487-93.
21. Mellman TA, Davis GC. Combat-related flashbacks in posttraumatic stress disorder: phenomenology and similarity to panic attacks. J Clin Psychiatry 1985; 46: 379-82.
22. Bradwejn J, Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 1994; 151(2): 261-3.
23. Yeragani VK, Pohl R, Balon R, Rainey JM, Berchou R, Ortiz A. Sodium lactate infusions after treatment with tricyclic antidepressants: behavioural and physiological findings. Biol Psychiatry 1988; 24(7): 767-74.
24. Woods SW, Charney DS, Delgado PL, Henninger GR. The effect of long-term imipramine treatment on carbon-dioxide-induced anxiety in panic disorder patients. J Clin Psychiatry 1990; 51: 505-7.
25. Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 1997; 17(2): 97-101.
26. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide in patients with panic disorder. J Psychiatry Neurosci 1997; 22: 332-40.
27. Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induces anxiety in panic disorder. Psychiatry Res 1993; 48: 119-33.
28. Nardi AE, Valenca AM, Nascimento I, Mezzasalma MA, Zin WA. Double-blind acute clonazepam vs. placebo in carbon dioxideinduced panic attacks. Psychiatry Res 2000; 94(2): 179-84.
29. Cowley DS, Dager SR, Roy-Byrne PP, Avery DH, Dunner DL. Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol Psychiatry 1991; 30(1): 49-56.
30. Sanderson WC, Wetzler S, Asnis GM. Alprazolam blockade of CO2-provoked panic in patients with panic disorder. Am J Psychiatry 1994; 151(8): 1220-2.
31. Kellner M. Experimental panic provocation in healthy man - a translational role in anti-panic drug development? Dial Clin Neuroscience; 13(4): 485-93.
32. Hoge CW, Terhakopian A, Castro CA, Messer SC, Engel CC. Association of posttraumatic stress disorder with somatic symptoms, health care visits, and absenteeism among Iraq war veterans. Am J Psychiatry 2007; 164(1): 150-3.
33. Boscarino JA. Posttraumatic stress disorder and mortality among U.S. Army veterans 30 years after military service. Ann Epidemiol 2006; 16(4): 248-56.
34. Pitts FM, McClure JN. Lactate metabolism in anxiety neurosis. N Engl J Med 1967; 277(25): 1329-36.
35. Shekhar A, Sajdyk TJ, Gehlert DR, Rainnie DG. The amygdala, panic disorder, and cardiovascular responses. Ann NY Acad Sci. 2003; 985: 308-25.
36. Fyer AJ, Gorman JM, Liebowitz MR, et al. Sodium lactate infusion, panic attacks, and ionized calcium. Biol Psychiatry 1984; 19(10): 1437-47.
37. Esquivel G, Schruers KR, Maddock RJ, Colasanti A, Griez EJ. Acids in the brain: a factor in panic? J Psychopharmacol 2010; 24(5): 639-47.
38. Peskind ER, Jensen CF, Pascualy M, et al. Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol Psychiatry 1998; 44(10): 1007-16.
39. Gorman JM, Battista D, Goetz RR, et al. A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. Arch Gen Psychiatry 1989; 46(2): 145-50.
40. Kellner M, Knaudt K, Jahn H, Holsboer F, Wiedemann K. Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. J Psychiatr Res 1998; 32(1): 37-48.
41. Molosh AI, Johnson PL, Fitz SD, Dimicco JA, Herman JP, Shekhar A. Changes in central sodium and not osmolarity or lactate induce panic-like responses in a model of panic disorder. Neuropsychopharmacology 2010; 35(6): 1333-47.
42. Rainey JM, Aleem A, Ortiz A, Yeragani V, Pohl R, Berchou R. A laboratory procedure for the induction of flashbacks. Am J Psychiatry 1987; 144(10): 1317-9.
43. Jensen CF, Keller TW, Peskind ER, et al. Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Am J Psychiatry 1997; 154(2): 266-8.
44. Jensen CF, Peskind ER, Keller TW, McFall ME, Raskind MA. Comparison of sodium lactate-induced panic symptoms between panic disorder and posttraumatic stress disorder. Depress Anxiety 1998; 7(3): 122-5.
45. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF. Measurement of lactate-induced panic and anxiety. Psych Res 1987; 20(2): 97-105.
46. Liebowitz MR, Fyer AJ, Gorman JM, et al. Lactate provocation of panic attacks. 1: Clinical and behavioral findings. Arch Gen Psychiatry 1984; 41(8): 764-70.
47. Cowley DS, Arana GW. The diagnostic utility of lactate sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47(3): 277-84.
48. Van den Hout, MA, Griez, E. Panic symptoms after inhalation of carbon dioxide. Br J Psychiatry 1984; 144: 503-7.
49. Gorman JM, Fyer MR, Goetz R, et al. Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 1988; 45(1): 31-9.
50. Griez E, Zandbergen J, Pols H, de Loof C. Response to 35% CO2 as a marker of panic in severe anxiety. Am J Psychiatry 1990; 147(6): 796-7.
51. Perna G, Barbini B, Cocchi S, Bertani A and Gasperini M. 35% CO2 challenge in panic and mood disorders. J Affect Disord 1995; 33(3): 189-94.
52. Griez EJ, Colasanti A, van Diest R, Salamon E, Schruers K. Carbon Dioxide Inhalation Induces Dose-Dependent and Age-Related Negative Affectivity. PLoS ONE 2007; 2(10): e987.
53. Ogliari A, Tambs K, Harris JR, et al. The relationships between adverse events, early antecedents, and carbon dioxide reactivity as an intermediate phenotype of panic disorder: a general population study. Psychother Psychosom 2010; 79(1): 48-55.
54. Muhtz C, Daneshi J, Braun M, Kellner M. Carbon-Dioxide- Induced Flashback in a Healthy Man with a History of Near- Drowning. Psychother Psychosom 2010; 80(1): 55-6.
55. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 1993; 50(4): 306-17.
56. Ziemann AE, Allen JE, Dahdaleh NS, et al. The amygdala is a chemosensor that detects carbon dioxide and acidosis to elicit fear behavior. Cell 2009; 139(5): 1012-21.
57. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157: 493-505.
58. Gorman JM, Kent J, Martinez J, Browne S, Coplan J, Papp LA. Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder: evidence for a central fear mechanism. Arch Gen Psychiatry 2001; 58(2): 125-31.
59. Bailey JE, Argyropoulos SV, Lightman SL, Nutt DJ. Does the brain noradrenaline network mediate the effects of the CO2 challenge? J Psychopharmacol 2003; 17(3): 252-9.
60. Talesnik B, Berzak E, Ben-Zion I, Kaplan Z, Benjamin J. Sensitivity to carbon dioxide in drug-naive subjects with post-traumatic stress disorder. J Psych Res 2007; 41(5): 451-4.
61. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979; 41: 209-18.
62. Muhtz C, Yassouridis A, Daneshi J, Braun M, Kellner M. Acute panicogenic, anxiogenic and dissociative effects of carbon dioxide inhalation in patients with post-traumatic stress disorder (PTSD). J Psych Res 2011; 45(7): 989-93.
63. Pastucha P, Prasko J, Grambal A, et al. Panic disorder and dissociation - comparison with healthy controls. Neuro Endocrinol Lett 2009; 30(6): 774-8.
64. Bryant RA. Does dissociation further our understanding of PTSD? J Anxiety Disord. 2007; 21(2): 183-91.
65. Leonard KN, Telch JM, Harrington PJ. Dissociation in the laboratory: a comparison of strategies. Beh Res Ther 1999; 37(1): 49-61.
66. Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res 2009; 1293: 13-23.
67. Yehuda R, Southwick S, Giller EL, Ma X, Mason JW. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 1992; 180(5): 321-5.
68. Perry BD, Filler EL, Southwick SM. Altered pIatelet alpha-2- adrenergic binding sites in posttraumatic stress disorder. Am J Psychiatry 1987; 144(11): 1511-2.
69. Mellman TA, Kumar A, Kulick-Bell R, Kumar M, Nolan B. Nocturnal/daytime urine noradrenergic measures and sleep in combatrelated PTSD. Biol Psychiatry 1995; 38(3): 174-9.
70. Geracioti TD, Baker DG, Ekhator NN, West SA. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158(8): 1227-30.
71. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992; 86(4): 273-82.
72. Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry 2000; 47(6): 526-39.
73. Guthrie SK, Grunhaus L, Pande AC, Hariharan M. Noradrenergic response to intravenous yohimbine in patients with depression and comorbidity of depression and panic. Biol Psychiatry 1993; 34(8): 558-61.
74. Gurguis GNM, Vittone BJ, Uhde TW. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psych Res 1997; 71(1): 27-39.
75. Southwick SM, Krystal JH, Morgan CA, et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50(4): 266-74.
76. Argyle N, Deltito J, Allerup P, Maier W, Albus M, Nutzinger D. The Panic-Associated Symptom Scale: measuring the severity of panic disorder. Acta Psychiatr Scand 1991; 83(1): 20-6.
77. Southwick SM, Krystal JH, Bremner JD, et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1997; 54(8): 749-58.
78. Bremner JD, Ng CK, Staib L, et al. PET measurement of cerebral metabolism following a noradrenergic challenge in patients with posttraumatic stress disorder and in healthy subjects. J Nucl Med 1993; 3334: 205-6.
79. Bremner JD, Innis RB, Ng CK, et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry 1997; 54(3): 246-54.
80. Southwick SM, Morgan CA, III, Charney DS, High JR. Yohimbine use in a natural setting: Effects on posttraumatic stress disorder. Biol Psychiatry 1999; 46(3): 442-4.
81. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic Mechanisms in Stress and Anxiety: II. Clinical Studies. Synapse 1996; 23: 39-51.
82. Jans LA, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007; 12(6): 522-43.
83. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998; 44(5): 313-23.
84. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995; 14(3): 187-202.
85. Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG. Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. Eur Neuropsychopharmacol 2007; 17(10): 637-42.
86. Broocks A, Bandelow B, George A, et al. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 2000; 15(3): 153-61.
87. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 1991; 30(10): 973-84.
88. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989; 28(3): 295-306.
89. Mortimore C, Anderson IM. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacol 2000; 149(3): 251-8.
90. Davis LL, Clark DM, Kramer GL, Moeller FG, Petty F. Dfenfluramine challenge in posttraumatic stress disorder. Biol Psychiatry 1999; 45(7): 928-30.
91. Schweitzer I, Morris P, Hopwood M, Maguire K, Norman T. Prolactin response to d-fenfluramine in combat-related posttraumatic stress disorder. Int J Neuropsychopharmacol 2004; 7(3): 291-8.
92. Davies SJ, Esler M, Nutt DJ. Anxiety--bridging the heart/mind divide. J Psychopharmacol. 2010; 24(5): 633-8.
93. Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 2005; 30(3): 167-75.
94. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998; 55(8): 715-20.
95. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry 2003; 64(12): 1421-5.
96. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006; 184(1): 21-5.
97. Pae CU, Marks DM, Han C, Masand PS, Patkar AA. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol 2009; 24(1): 29-33.
98. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996; 57(9): 390-4.
99. Viola J, Ditzler T, Batzer W, et al. Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990-1995. Mil Med 1997; 162(9): 616-9.
100. Harvey BH, Oosthuizen F, Brand L, Wegener G, Stein DJ. Stressrestress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology 2004; 175(4): 494-502.
101. Geuze E, van Berckel BN, Lammertsma AA, et al. Reduced GABAA benzodiazepine receptor binding in veterans with posttraumatic stress disorder. Mol Psychiatry 2008; 13(1): 74-83.
102. Vaiva G, Boss V, Ducrocq F, et al. Relationship between posttrauma GABA plasma levels and PTSD at 1-year follow-up. Am J Psychiatry 2006; 163(8): 1446-8.
103. Shalev AY, Sahar T, Freedman S. A prospective study of heart rate responses following trauma and the subsequent development of posttraumatic stress disorder. Arch Gen Psychiatry 1998; 55: 553-9.
104. Swanson LW, Petrovich GD. What is the amygdala? Trends Neurosci 1998; 21: 323-31.
105. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry 2000; 157(7):1120-6.
106. Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47(10): 917-25.
107. Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 1991; 36(2): 115-27.
108. Ströhle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 1998; 155(5): 610-2.
109. Randall PK, Bremner JD, Krystal JH, et al. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biol Psychiatry 1995; 38(5): 319-24.
110. Coupland NJ, Lillywhite A, Bell CE, Potokar JP, Nutt DJ. A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. Biol Psychiatry 1997; 41(9): 988-90.
111. Bradweijn J. Neurobiolocical investigations into the role of cholezystokinin in panic disorder. J Psychiatr Neurosci 1993; 18: 178-88.
112. Akiyoshi J, Isogawa K, Tsutsumi T, et al. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia. Biol Psychiatry 1997; 42(2): 151-4.
113. Brambilla F, Bellodi L, Perna G, Garberi A, Panerai A, Sacerdote P. Lymphocyte cholecystokinin concentrations in panic disorder. Am J Psychiatry 1993; 150(7): 1111-3.
114. Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 1999; 4(3): 284-5.
115. Kellner M, Levengood R, Yehuda R, Wiedemann K. Provocation of a posttraumatic flashback by cholecystokinin tetrapeptide? Am J Psychiatry 1998; 155(9): 1299.
116. Kellner M, Wiedemann K, Yassouridis A, et al. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biol Psychiatry 2000; 47(2): 107-11.
117. Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986; 174: 727-35.
118. Skelton K, Ressler KJ, Norrholm SD, Jovanovic T, Bradley-Davino B. PTSD and gene variants: New pathways and new thinking. Neuropharmacology 2012: 62(2): 628-37.
119. Davidson JR, Kudler HS, Saunders WB, Smith RD. Symptom and comorbidity patterns in World War II and Vietnam veterans with posttraumatic stress disorder. Compr Psychiatry 1990; 31(2): 162-70.
120. Cougle JR, Feldner MT, Keough ME, Hawkins KA, Fitch KE. Comorbid panic attacks among individuals with posttraumatic stress disorder: associations with traumatic event exposure history, symptoms, and impairment. J Anxiety Disord 2010; 24(2): 183-8.
121. Chantarujikapong SI, Scherrer JF, Xian H, et al. A twin study of generalized anxiety disorder symptoms, panic disorder symptoms and post-traumatic stress disorder in men. Psychiatry Res 2001; 103(2-3): 133-45.
122. Safadi G, Bradwejn J. Relationship of panic disorder to posttraumatic stress disorder. Arch Gen Psychiatry 1995; 52(1): 76-8.
123. Eser D, Schüle C, Baghai T, et al. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology 2007; 192(4): 479-87.